Últimas noticias sobre AEON Biopharma (AMEX:AEON) Bolsa

AEON Biopharma

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEON

ANIP

BBAI

BLRX

CFFI

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SIBN

SLXN

SOBR

SONM

TNXP

WHLR

TSMC y otras acciones destacaron en el premercado tras reportar ganancias récord. Descubre los mayores ganadores y perdedores.

Acciones de Taiwan Semiconductor (TSM) suben alrededor del 5%; 20 acciones en movimiento en el premercado de EE.UU.

Equities

Eurozone

Commodities

Intraday Update

BHAT

FUBO

SPRC

Los mercados financieros avanzan con el Dow Jones subiendo 200 puntos. Conoce las acciones ganadoras, caídas y tendencias en materias primas.

Índices bursátiles al alza: Las acciones tecnológicas impulsan a Wall Street este lunes

ACON

BCTX

CPHC

EKSO

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

KITT

LDTC

MBOT

MEGL

MNSO

NSTS

SPPL

WFCF

Explora los mayores movimientos en el premercado con ganancias superiores al 100% y pérdidas significativas antes de la apertura.

Acciones de Smart Share Global se disparan un 44%; 20 acciones que se mueven en el premercado

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma Inc

AEON CREDIT SERVICE ASIA by Aeon Credit Service Asia Company Ltd

AEON Co Ltd

AEON DELIGHT CO LTD by Aeon Delight Co., Ltd.

AEON DELIGHT Co Ltd

AEON FANTASY CO LTD by AEON Fantasy Co., Ltd.

AEON FINCL SVCS JPN ORD by Aeon Financial Services Co., Ltd.

AEON Financial Service Co Ltd

AEON Mall Co Ltd

AEON REIT INVT CORP by AEON REIT INVT CORP.

AEON REIT Investment Corp

Aeon Credit Service (Asia) Co Ltd

Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) shares are trading slightly <a href="http://benzinga.com/pressreleases/25/02/b43522213/hilton-reports-fourth-quarter-and-record-full-year-results" target="_blank" rel="noreferrer noopener">higher on Thursday</a> after the company reported fourth-quarter earnings that beat the Street consensus.
<ul>
<li>Q4 adjusted earnings per share of $1.76, beating the street view of $1.68. </li>
<li>Quarterly sales of $2.783 billion outpaced the analyst consensus estimate of $2.77 billion.</li>
<li>22,600 rooms added to Hilton&#8217;s system, resulting in 98,400 room openings for the full year.</li>
<li>This contributed to net unit growth of 7.3% from Dec. 31, 2023.</li>
<li>System-wide comparable Revenue Per Available Room, or RevPAR, in the quarter under review increased 3.5% year over year. Management and franchise fee revenues increased 4.8%.</li>
</ul>
CEO Christopher J. Nassetta said all segments drove RevPAR outperformance. Nassetta also cited strong trends in leisure occupancy, as well as continued growth in business transient and group results.
HIlton expects &#8220;favorable trends to continue into 2025,&#8221; Nassetta said.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/02/43518087/trump-meme-coin-jumps-4-27-outpaces-bitcoin-ethereum-and-dogecoin-but-its-still-no-where-near-january-highs" rel="noreferrer noopener">TRUMP Meme Coin Jumps 4.27%, Outpaces Bitcoin, Ethereum And Dogecoin, But It&#8217;s Still Nowhere Near January Highs</a>
&#8220;We also delivered the highest number of approvals, construction starts and openings in our history in 2024,&#8221; he added.
Adjusted EBITDA in the quarter under review totaled $858 million, higher than $803 million in the year-ago period.
As of Dec. 31, the company has $11.2 billion of debt outstanding. 
Outlook: Hilton expects first-quarter adjusted EPS to be between $1.57 and $1.63, below the $1.67 estimate.
Hilton has announced that it expects its first quarter system-wide RevPAR to increase by 2.5% to 3.5% year-over-year on a currency-neutral basis.
&#8220;With a development pipeline of nearly half a million rooms, we are confident that we are well positioned to deliver net unit growth between 6% and 7% in 2025,&#8221; the CEO said.
For 2025, it anticipates adjusted EPS of $7.71 to $7.82, higher than the $7.04 estimate. Additionally, the company has projected net unit growth for the full fiscal year 2025 (FY25) to be between 6% and 7%.
Price Action: HLT shares are trading higher by 5.72% to $272.60 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/02/43517995/amazons-remarkable-alexa-is-coming-heres-what-to-expect-from-the-ai-overhaul-and-its-potential-10-monthly-fee" target="_blank" rel="noreferrer noopener">Amazon's ‘Remarkable Alexa' Is Coming—Here's What To Expect From The AI Overhaul And Its Potential $10 Monthly Fee</a></li>
</ul>

General

Hilton Stock Soars As Q4 Beats Estimates Amid Strength In Revenue Per Available Room

Wells Fargo analyst Andrew Bauch maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Overweight and raises the price target from $240 to $270.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Fiserv, Raises Price Target to $270

WIIM

Lincoln National shares are trading higher after the company reported better-than-expected Q4 financial results.

Wedbush analyst Seth Basham maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Neutral and raises the price target from $1200 to $1350.

ORLY

Wedbush Maintains Neutral on O'Reilly Automotive, Raises Price Target to $1350

On Wednesday, Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) authorized to pursue a plan to separate BD&#8217;s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43511126/bd-announces-intent-to-separate-biosciences-and-diagnostic-solutions-business-to-enhance-focus-dri" rel="noreferrer noopener">and capital allocation</a>.
Following the separation, New BD will be a pure-play medical technology company. It expects to drive concentrated investments in high-impact R&amp;D and disciplined capital allocation, including growth-accretive M&amp;A.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit</a>
Medical Essentials includes BD&#8217;s Medication Delivery Solutions and Specimen Management businesses, which manufacture products such as IV catheters, PICCS, flush and other essential vascular access and management solutions, blood collection solutions, syringes, and advanced needle technologies.
Connected Care includes BD&#8217;s Medication Management Solutions and Advanced Patient Monitoring businesses with smart devices that use automation, artificial intelligence, and analytics.
BioPharma Systems provides biologic drug delivery, development, and manufacturing of drug delivery devices for the pharmaceutical industry.
Interventional, which includes BD&#8217;s Urology &amp; Critical Care, Peripheral Intervention, and Surgery businesses, caters to conditions such as urinary incontinence, peripheral vascular disease, cancer, and hernias.
After the separation, the New BD is expected to have fiscal 2024 revenue of approximately&nbsp;$17.8 billion. Biosciences and Diagnostic Solutions is expected to have approximately&nbsp;$3.4 billion&nbsp;in fiscal 2024 revenue.
The company expects to announce more specifics on the separation plans by the end of fiscal 2025 and intends to target completion of the transaction in fiscal 2026.
In April 2022, Becton Dickinson spun off&nbsp;Embecta Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NYSE">EMBC</a>), a diabetes device maker, <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">into a standalone entity</a>.
In November, the company announced that it had decided to discontinue its insulin patch pump program and would&nbsp;<a target="_blank" href="https://www.benzinga.com/24/11/42197315/becton-dickinson-spinoff-embecta-stops-insulin-patch-pump-program-plans-restructuring-stock-jumps" rel="noreferrer noopener">initiate a restructuring plan</a>.
In July, Embecta, a manufacturer of disposable&nbsp;insulin pen needles&nbsp;and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/07/39916116/insulin-device-maker-embecta-weighs-sale-after-70-share-decline-following-becton-dickinson-spin-off" rel="noreferrer noopener">giant&nbsp;Becton, Dickinson</a>.
Concurrently, BD reported first-quarter 2025 adjusted EPS of $3.43 beating the consensus of $2.98. The company&#8217;s sales increased 9.8% year-over-year to $5.17 billion, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $5.1 billion</a>.
Guidance: BD updated its fiscal year 2025 revenue guidance from $21.9 billion-$22.1 billion to $21.7 billion-$21.9 billion compared to the consensus of $21.93 billion.
The company expects adjusted EPS of $14.30-$14.60, up from $14.25-$14.60 compared to the consensus of $14.40.
Price Action: BDX stock is down 3.88% at $235.56 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43527607/conocophillips-beats-q4-revenue-and-eps-estimates-sets-10b-return-of-capital-target" target="_blank" rel="noreferrer noopener">ConocoPhillips Beats Q4 Revenue And EPS Estimates, Sets $10B Return of Capital Target</a></li>
</ul>

Earnings

Guidance

Health Care

EMBC

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business

Evercore ISI Group analyst Elizabeth Anderson maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and raises the price target from $240 to $260.

ALGN

Evercore ISI Group Maintains Outperform on Align Tech, Raises Price Target to $260

Wells Fargo analyst Joe O'Dea maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Overweight and raises the price target from $92 to $98.

Wells Fargo Maintains Overweight on Johnson Controls Intl, Raises Price Target to $98

NVST

Envista Holdings shares are trading higher after the company reported better-than-expected Q4 financial results. Also, Wells Fargo and Morgan Stanley raised their respective price targets on the stock.

Wells Fargo analyst Joseph O'Dea maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Underweight and lowers the price target from $250 to $245.

Wells Fargo Maintains Underweight on Illinois Tool Works, Lowers Price Target to $245

Darling Ingredients shares are trading higher after the company reported better-than-expected Q4 EPS results.

Wedbush analyst Seth Basham reiterates Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Neutral and maintains $250 price target.

Reiteration

CVNA

Wedbush Reiterates Neutral on Carvana, Maintains $250 Price Target

CENT

Central Garden shares are trading higher after the company reported better-than-expected Q1 financial results.

Wells Fargo analyst Joseph O'Dea maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Overweight and raises the price target from $140 to $142.

Wells Fargo Maintains Overweight on Emerson Electric, Raises Price Target to $142

Wells Fargo analyst Colin Langan maintains Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) with a Underweight and lowers the price target from $9 to $8.

Wells Fargo Maintains Underweight on Ford Motor, Lowers Price Target to $8

Haemonetics shares are trading lower after the company reported Q3 financial results and missed its revenue estimate.

Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) with a Equal-Weight and lowers the price target from $74 to $70.

CNMD

Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $70

Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Outperform and raises the price target from $34 to $36.

KURA

Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $36

Semiconductor equipment and material supplier Entegris&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) reported its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43522215/entegris-reports-results-for-fourth-quarter-of-2024" rel="noreferrer noopener">fiscal fourth-quarter 2024</a> earnings Thursday before the market opened.
What To Know: The company reported adjusted EPS of 84 cents, topping <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of 78 cents</a>. Entegris reported sales of $849.84 million, marking a 5% growth year-over-year and quashing the analyst consensus estimate of $823.12 million.
Segments: Materials Solutions revenue declined 1.1% to $361.08 million. Advanced Purity Solutions revenue grew by 9.2% to $491.19 million.
However, the company&#8217;s adjusted net sales, excluding the impact of divestitures, increased by 11% Y/Y.
Materials Solutions segment profit grew 45% to $771.22 million. Purity Solutions segment profit increased 14.4% to $134.97 million.
Entegris also reported other key financial indicators, including an adjusted EBITDA margin of 29.2% (versus 26.0% Y/Y), an adjusted operating margin of 23.5% (versus 20.7% Y/Y), and an adjusted gross margin of 45.6% (versus 42.4% Y/Y).
CEO Bertrand Loy noted that Entegris continued to outperform the market, with EBITDA growth twice its sales growth rate.
Loy flagged limited visibility outside of advanced logic and AI-driven applications as it enters 2025. The company will continue to fund critical investments that improve its long-term competitiveness and position it for the industry upturn. Loy found the company well-positioned for the upcoming technology node transitions, likely generating incremental content per wafer opportunities.
Outlook: The company issued guidance for the fiscal first quarter of 2025. Entegris anticipates sales between $775 million-$805 million versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimates of $796.26 million</a>. Furthermore, the company expects adjusted EPS from 64 cents to 71 cents below analyst estimates of 74 cents.
Entegris stock lost over 12% in the last 12 months as multiple Wall Street firms <a target="_blank" href="https://www.benzinga.com/quote/ENTG/analyst-ratings" rel="noreferrer noopener">slashed their price targets</a> after a dismal <a target="_blank" href="https://www.benzinga.com/news/24/11/41717366/whats-going-on-with-entegris-shares-monday" rel="noreferrer noopener">third-quarter print</a>. Loy told customers with significant exposure to AI applications performed well, but the rest of the industry continues to be challenged.
Price Action: ENTG stock is up 5.38% at $109.49 at the last check in Thursday.
Read next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43528027/hersheys-stock-pops-as-q4-earnings-beat-expectationsbut-cocoa-prices-loom-over-2025-outlook" target="_blank" rel="noreferrer noopener">Hershey&#8217;s Stock Pops As Q4 Earnings Beat Expectations—But Cocoa Prices Loom Over 2025 Outlook</a></li>
</ul>
Photo via Shutterstock

ENTG

Entegris Q4 Earnings: Revenue And Profit Beat, Warns of 2025 Uncertainty Beyond AI Growth

ASTS

AST SpaceMobile shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $30.

Wells Fargo analyst Vik Chopra maintains Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) with a Equal-Weight and raises the price target from $20 to $21.

Wells Fargo Maintains Equal-Weight on Envista Holdings, Raises Price Target to $21

The latest announcement is out from AEON Biopharma (AEON). AEON Biopharma, Inc. recently updated its investor relations page with a new corporate p...

AEON Biopharma Releases New Corporate Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AEON Biopharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aeon-stock-quote/">AEON</a>) just reported results for the second quarter of 2024.<ul><li>AEON Biopharma reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/aeon-stock-earnings-aeon-biopharma-for-q2-of-2024/">AEON Stock Earnings: AEON Biopharma Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AEON Stock Earnings: AEON Biopharma Beats EPS for Q2 2024

AEON Biopharma reports Q2 results

AEON receives positive outcome in FDA biosimilar advisory meeting

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on AEON Biopharma (AEON – Research Report) and keeping the price target at $5.00....

Buy Rating on AEON Biopharma: Strategic FDA Alignment and Positive Long-Term Revenue Projections

AEON Biopharma ( ($AEON) ) has issued an update. AEON Biopharma, Inc. has recently updated its investor community by releasing a new corporate pres...

AEON Biopharma Releases New Investor Presentation

AEON Biopharma GAAP EPS of -$0.16

AEON Biopharma announces share offering

AEON Biopharma ( ($AEON) ) just unveiled an update. AEON Biopharma announced the pricing of a $20 million underwritten public offering to support t...

AEON Biopharma's $20M Offering for ABP-450 Development

AEON Biopharma (AEON) announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be app...

Comments

AEON Biopharma

Noticias

Últimas noticias sobre AEON Biopharma (AMEX:AEON) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL